Ryvu Therapeutics (WAR:RVU) Tariff Resilience Score: 0/10 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:RVU Ryvu Therapeutics SA WAR:RVU
66 GF Score
Price zł15.00
GF Value zł45.94
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Tariff Resilience Score?

Ryvu Therapeutics has the Tariff Resilience Score of 0, which implies that the company might have .

Ryvu Therapeutics has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Ryvu Therapeutics might have .

Ryvu Therapeutics  (WAR:RVU) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Ryvu Therapeutics Tariff Resilience Score Related Terms

WAR:RVU
66GF Score
Ryvu Therapeutics SA WAR:RVU
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ryvu Therapeutics (WAR:RVU) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł15.00 is trading 67.3% below its estimated GF Value™ of zł45.94. GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.

Key valuation signals for WAR:RVU:

  • Tariff Resilience Score: 0
  • GF Value™: zł45.94 vs. price of zł15.00 (67.3% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the WAR:RVU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges 9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for WAR:RVU

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł15.00
Price
zł45.94
GF Value